A photo of Joseph G. Pressey.

Director, Musculoskeletal Tumor Center

Co-Director, Young Adult Oncology Program

Co-Director, Research Solid Tumor Program

Professor, UC Department of Pediatrics

513-636-0670

513-636-3549

Board Certified

My Biography & Research

Biography

Dr. Pressey graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children's Hospital Medical Center. He trained in pediatric hematology-oncology at the Children's Hospital of Philadelphia where he developed a keen interest in the biology and therapy of pediatric sarcomas. He spent 11 years at the University of Alabama at Birmingham School of Medicine and Children's Hospital of Alabama where he functioned as the principal investigator (PI) for the Children's Oncology Group (COG) Phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).

Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children's to direct the Sarcoma and Young Adult Oncology Programs in 2014. He is appointed Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine and functions as the Cincinnati Children's Institutional PI for the COG Pediatric Early Phase Clinical Trials Network (PEP-CTN) and SARC, as well as, for many industry-sponsored trials.

Clinical Interests

Pediatric and young adult patients with musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; desmoid tumors; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary

Research Interests

The development of novel therapies for pediatric sarcomas and rare tumors.

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sarcoma, Young Adult Cancer, Neurofibromatosis

Research Divisions

Oncology, Cancer and Blood Diseases



Blog Posts

The Challenges of Cancer Therapy in Adolescents and Young Adults

BlogCancer and Blood Diseases

The Challenges of Cancer Therapy in Adolescents and Young Adults

By Joseph Pressey, MD3/29/2018

My Locations

My Education

MD: Medical College of Georgia, Augusta, GA, 1995.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.

Certification: Pediatric Hematology-Oncology, 2002.

My Publications

Selected Publication

Challenges in the Treatment of Sarcomas of Adolescents and Young Adults. Rotz, SJ; Nagarajan, R; Sorger, JI; Pressey, JG. Journal of Adolescent and Young Adult Oncology. 2017; 6:406-413.

Active and Protected: Developing a "Safer Sex " Handout for Adolescents and Young Adults with Cancer. McGrady, ME; Bredenberg, DL; Danziger-Isakov, L; Rios, J; Frias, O; West, MY; Fisher, P; Salloum, R; Pressey, JG; Norris, RE. Journal of Adolescent and Young Adult Oncology. 2021; 10:351-354.

Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis. Wang, Y; Pandey, RN; Roychoudhury, K; Milewski, D; Kalin, TV; Szabo, S; Pressey, JG; Hegde, RS. Molecular Cancer Therapeutics. 2021; 20:803-815.

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski, D; Shukla, S; Gryder, BE; Pradhan, A; Donovan, J; Sudha, P; Vallabh, S; Pyros, A; Xu, Y; Barski, A; et al. Oncogene. 2021; 40:2182-2199.

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Geller, JI; Pressey, JG; Smith, MA; Kudgus, RA; Cajaiba, M; Reid, JM; Hall, D; Barkauskas, DA; Voss, SD; Cho, SY; et al. Cancer. 2020; 126:5303-5310.

Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6 -Amplified Osteosarcoma. Lazow, MA; Johnson, SL; Johnson, ND; Breneman, JC; Dexheimer, PJ; Szabo, S; Pressey, JG. JCO Precision Oncology. 2020; 498-504.

Reply to comment on: Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations. Turpin, B; Todd, KE; Pressey, JG. Pediatric Blood and Cancer. 2020; 67.

Pediatric BRAF (V600E)–Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib. Cramer, S; Marcus, MA; Ramkissoon, S; Szabo, S; Pressey, JG. JCO Precision Oncology. 2020; 801-805.

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Gounder, M; Schöffski, P; Jones, RL; Agulnik, M; Cote, GM; Villalobos, VM; Attia, S; Chugh, R; Chen, TW W; Jahan, T; et al. The Lancet Oncology. 2020; 21:1423-1432.

Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations. Todd, K; Kim, HK; Szabo, S; Johnson, S; Pressey, J; Nagarajan, R; Sorger, J; Dasgupta, R; Turpin, B. Pediatric Blood and Cancer. 2020; 67.